Journal
HEART FAILURE CLINICS
Volume 8, Issue 3, Pages 461-+Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.hfc.2012.04.010
Keywords
Pulmonary hypertension; Interstitial lung disease; Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis
Categories
Funding
- F32 training grant [NIH 5T32HL098040-01]
- Gilead
- United Therapeutics
- Pfizer
- Novartis
- Bayer
- GeNO
Ask authors/readers for more resources
The pathophysiology of pulmonary hypertension (PH) in parenchymal lung diseases is partially related to hypoxic pulmonary vasoconstriction. PH treatment is controversial for these patients. This article focuses on group III PH, namely PH attributable to lung diseases and/or hypoxia. Group III includes chronic obstructive pulmonary disease and interstitial lung diseases, the most common parenchymal lung diseases associated with PH. It also includes sleep-disordered breathing and hypoventilation from any cause. Other parenchymal lung diseases associated with PH, namely sarcoidosis and systemic vasculitides (group V), are discussed. The data describing PH in specific parenchymal diseases are reviewed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available